Champions Oncology Inc (OTCMKTS:CSBR) CEO Joel Ackerman bought 8,202 shares of the firm’s stock in a transaction dated Friday, October 7th. The shares were acquired at an average price of $1.63 per share, for a total transaction of $13,369.26. Following the transaction, the chief executive officer now directly owns 1,027,764 shares in the company, valued at $1,675,255.32. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Joel Ackerman also recently made the following trade(s):
- On Friday, September 23rd, Joel Ackerman bought 33 shares of Champions Oncology stock. The shares were acquired at an average price of $1.65 per share, for a total transaction of $54.45.
- On Wednesday, September 21st, Joel Ackerman bought 5,000 shares of Champions Oncology stock. The shares were acquired at an average price of $1.66 per share, for a total transaction of $8,300.00.
Champions Oncology Inc (OTCMKTS:CSBR) opened at 1.66 on Tuesday. The stock’s market cap is $18.21 million. Champions Oncology Inc has a one year low of $1.11 and a one year high of $5.49. The firm has a 50-day moving average price of $1.68 and a 200-day moving average price of $2.58.
Champions Oncology (OTCMKTS:CSBR) last issued its quarterly earnings data on Friday, September 9th. The company reported ($0.15) earnings per share for the quarter. The business earned $3.70 million during the quarter.
About Champions Oncology
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.